DEF: Jasper Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Jasper Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on July 3, 2025, to vote on director elections, auditor ratification, executive compensation, and other matters.

Summary

• Jasper Therapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on Thursday, July 3, 2025, at 10:00 a.m. Pacific Time.
• Stockholders will vote on the election of three Class I directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, an advisory vote on executive compensation, and an advisory vote on the frequency of future advisory votes on executive compensation.
• The board of directors has set May 9, 2025, as the record date for determining stockholders eligible to vote at the Annual Meeting.
• The company will mail a Notice of Internet Availability of Proxy Materials on or about May 23, 2025, containing instructions on how to access the proxy statement and the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The board of directors recommends voting FOR the election of the director nominees, FOR the ratification of the auditor, FOR the approval of executive compensation, and FOR holding advisory votes on executive compensation every ONE year.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions. The sentiment is slightly positive due to the company's efforts to engage with stockholders and promote sustainability.

Positives

• The company is providing expanded access to stockholders by holding a virtual-only meeting.
• The virtual-only approach lowers costs and aligns with the company's broader sustainability goals.
• The board is encouraging stockholders to provide timely and valuable feedback on executive compensation matters.

Future Outlook

The document outlines the proposals to be voted on at the annual meeting, including advisory votes on executive compensation, which will inform future compensation decisions.

Management Comments

• We appreciate your continued support of Jasper.

Industry Context

This is a standard proxy statement for a publicly traded company, outlining the matters to be voted on at the annual meeting and providing information to stockholders to make informed decisions.

Comparison to Industry Standards

• The structure and content of this proxy statement are consistent with industry standards for publicly traded companies in the United States.
• The proposals to elect directors, ratify the auditor, and conduct advisory votes on executive compensation are common practices among publicly held companies.
• The company's approach to executive compensation and corporate governance appears to align with general practices in the biotechnology industry.

Related Party Transactions

• Judith Shizuru, a board member, receives $250,000 per year for consulting services.

Stakeholder Impact

• Shareholders are asked to vote on key decisions regarding the company's direction and governance.
• Executive officers' compensation is subject to advisory votes, potentially impacting their remuneration.
• The outcome of the votes will influence the company's corporate governance practices and executive compensation policies.

Next Steps

• Stockholders are urged to vote via the Internet or mail as soon as possible.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results in a Current Report on Form 8-K.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, executive compensation, PricewaterhouseCoopers, voting, corporate governance, Jasper Therapeutics